Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.30) by 53.33 percent. This is a 71.43 percent increase over losses of $(0.49) per share from the same period last year.